Edwards Lifesciences Co. (NYSE:EW) Position Increased by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP boosted its holdings in Edwards Lifesciences Co. (NYSE:EW - Free Report) by 27.9% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 2,995,208 shares of the medical research company's stock after buying an additional 653,577 shares during the quarter. Dimensional Fund Advisors LP owned 0.51% of Edwards Lifesciences worth $221,743,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Crowley Wealth Management Inc. purchased a new position in shares of Edwards Lifesciences in the fourth quarter worth approximately $26,000. Millstone Evans Group LLC purchased a new position in Edwards Lifesciences during the 4th quarter worth approximately $29,000. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in Edwards Lifesciences during the 4th quarter valued at $30,000. Roble Belko & Company Inc purchased a new stake in shares of Edwards Lifesciences in the fourth quarter valued at $46,000. Finally, Catalyst Capital Advisors LLC acquired a new stake in shares of Edwards Lifesciences in the fourth quarter worth $54,000. Institutional investors own 79.46% of the company's stock.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, CEO Bernard J. Zovighian sold 6,164 shares of Edwards Lifesciences stock in a transaction on Monday, March 10th. The shares were sold at an average price of $69.51, for a total transaction of $428,459.64. Following the sale, the chief executive officer now owns 59,083 shares in the company, valued at $4,106,859.33. The trade was a 9.45 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, VP Donald E. Bobo, Jr. sold 6,500 shares of the stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $75.75, for a total transaction of $492,375.00. Following the completion of the transaction, the vice president now owns 46,936 shares of the company's stock, valued at approximately $3,555,402. This represents a 12.16 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 71,853 shares of company stock worth $5,163,062. 1.29% of the stock is currently owned by company insiders.

Edwards Lifesciences Price Performance

Shares of NYSE:EW opened at $70.54 on Wednesday. The company has a market cap of $41.47 billion, a price-to-earnings ratio of 10.12, a PEG ratio of 4.82 and a beta of 1.15. The business has a 50 day moving average price of $71.07 and a 200 day moving average price of $70.95. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Co. has a twelve month low of $58.93 and a twelve month high of $95.25.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its quarterly earnings data on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, beating the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. Research analysts predict that Edwards Lifesciences Co. will post 2.45 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages recently issued reports on EW. Piper Sandler increased their price objective on Edwards Lifesciences from $70.00 to $73.00 and gave the stock a "neutral" rating in a research note on Wednesday, February 12th. Morgan Stanley increased their price target on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the stock an "equal weight" rating in a research report on Wednesday, February 12th. Evercore ISI decreased their price target on shares of Edwards Lifesciences from $75.00 to $73.00 and set an "in-line" rating for the company in a report on Wednesday, February 12th. Wolfe Research downgraded shares of Edwards Lifesciences from a "hold" rating to a "strong sell" rating in a research report on Wednesday, February 12th. Finally, Canaccord Genuity Group lifted their target price on shares of Edwards Lifesciences from $68.00 to $71.00 and gave the company a "hold" rating in a research note on Thursday, February 13th. One equities research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Hold" and an average target price of $78.55.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Co. (NYSE:EW - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.